AtaiBeckley (ATAI) Return on Assets (2021 - 2026)

AtaiBeckley's (ATAI) quarterly Return on Assets came in at 0.0% in Q1 2026.

AtaiBeckley (ATAI) Return on Assets (2021 - 2026) Analysis & Trends

AtaiBeckley's Return on Assets history runs 1 years deep, the most recent figure standing at 0.0% for Q1 2026.

For the quarter ending Q1 2025, Return on Assets fell 2.0% year-over-year to 0.02%; the trailing twelve-month figure through Mar 2025 stood at 0.02% (down 2.0% YoY), and the FY2024 full-year result was 0.01%, down 1.0% from the prior year.
Return on Assets eased to 0.02% in Q1 2025, from 0.0% in the prior quarter.
In the past five years, Return on Assets ranged from a high of 0.0% in Q1 2024 to a low of 2.03% in Q3 2021.
A 5-year average of 0.39% and a median of 0.0% in 2023 frame the typical range for Return on Assets.
Across the five-year window, Return on Assets surged 48 bps in 2022 and slipped 2 bps in 2025, its largest moves.
Tracing ATAI's Return on Assets over 5 years: stood at 0.49% in 2021, then soared by 99 bps to 0.0% in 2022, then jumped by 68 bps to 0.0% in 2023, then slumped by 78 bps to 0.0% in 2024, then plunged by 668 bps to 0.02% in 2025.
Business Quant data shows ATAI's Return on Assets at 0.02% in Q1 2025, 0.0% in Q2 2024, and 0.0% in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROA (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-0.69%
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.00%
4	NuCana	279.75 Bn	279.75 Bn	-	-0.01%
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	0.00%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.00%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-0.80%
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	0.00%
10	AtaiBeckley	2.56 Bn	2.56 Bn	-	-

Download Data